1 Recommendations
1.1
Olaparib with bevacizumab is recommended, within its marketing authorisation, for maintenance treatment of high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer:
-
has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab
-
is advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) and
-
is homologous recombination deficiency (HRD) positive (defined as having either a BRCA1 or BRCA2 mutation, or genomic instability).
Olaparib is only recommended if the company provides it according to the commercial arrangement.
Why the committee made these recommendations
This evaluation reviews the evidence for olaparib with bevacizumab for maintenance treatment of HRD-positive advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (NICE's technology appraisal guidance 693). It also reviews new evidence collected as part of the managed access agreement.
New clinical trial evidence shows that people taking olaparib with bevacizumab have more time before their cancer comes back than people having bevacizumab alone, and that they also live longer.
The most likely cost-effectiveness estimates for olaparib with bevacizumab are within what NICE considers an acceptable use of NHS resources. So, it is recommended for routine use in the NHS.